Icotrokinra vs LL-37
Overview
Icotrokinra and LL-37 are both immune support peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Icotrokinra and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | LL-37 | |
|---|---|---|
| Category | Immune Support | Immune Support |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | — | 2-5 mg |
| Frequency | — | twice weekly |
| Reported benefits | — | Antimicrobial activity, immune modulation, wound healing, anti-inflammatory |
| Reported side effects | — | Generally safe, minimal side effects |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while LL-37 falls under Immune Support. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Icotrokinra: FDA-approved. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Typical dosing for Icotrokinra is not catalogued. LL-37 is typically dosed at 2-5 mg (twice weekly).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and LL-37?
- Icotrokinra and LL-37 are both immune support peptides, but they differ in mechanism, dosing, and regulatory status. Icotrokinra is FDA-approved for one or more indications, whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is LL-37 used for?
- Antimicrobial defense peptide.
- Can you take Icotrokinra and LL-37 together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or LL-37 FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- LL-37 — full monograph: mechanism, research, dosing & references